Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients

J Dermatol. 2022 Apr;49(4):e125-e126. doi: 10.1111/1346-8138.16286. Epub 2021 Dec 27.

Authors

Kyoko Ikumi¹, Kan Torii¹, Yoko Sagawa¹, Yoshifumi Kanayama¹, Aya Nakada¹, Haruna Nishihara¹, Akimichi Morita¹

Affiliation

¹ Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

No abstract available

Publication types

Letter

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Humans
Insulin Resistance*
Phosphodiesterase 4 Inhibitors* / pharmacology
Phosphodiesterase 4 Inhibitors* / therapeutic use
Psoriasis* / drug therapy
Severity of Illness Index
Thalidomide / analogs & derivatives
Thalidomide / pharmacology
Thalidomide / therapeutic use
Treatment Outcome

Substances

Anti-Inflammatory Agents, Non-Steroidal
Phosphodiesterase 4 Inhibitors
Thalidomide
apremilast